FINASTERIDE 1 MGS
Finasteride (MK-906, INHIBAA by QUALTRA PHARMA, among other generic names) is a drug for the treatment of benign prostatic hyperplasia (BPH) and male pattern baldness (MPB). It is a type II 5α-reductase inhibitor; 5α-reductase, an enzyme, convertstestosterone to dihydrotestosterone (DHT).
Benign prostatic hyperplasia
Physicians use finasteride for the treatment of BPH, informally known as an enlarged prostate. Finasteride may improve the symptoms associated with BPH such as difficulty urinating, getting up during the night to urinate, hesitation at the start of urination, and decreased urinary flow. It provides less symptomatic relief than alpha-1 blockers such as tamsulosin and symptomatic relief is slower in onset (six months or more of treatment with finasteride may be required to determine the therapeutic results of treatment). Symptomatic benefits are mainly seen in those with prostate volume > 40 cm2. In long-term studies finasteride but not alpha-1 inhibitors reduce the risk of acute urinary retention (-57% at 4 years) and the need for surgery (-54% at 4 years). If the drug is discontinued, any therapeutic benefits reverse within about 6–8 months.
Male pattern baldness
Finasteride is used to treat male pattern hair loss (androgenetic alopecia) in men only. Treatment provides about 30% improvement in hair loss after six months of treatment, and effectiveness only persists as long as the drug is taken.
Finasteride is sometimes used in hormone replacement therapy for male-to-female transsexuals in combination with a form ofestrogen due to its antiandrogen properties. However, little clinical research of finasteride use for this purpose has been conducted and evidence of efficacy is limited.